上海市锦天城律师事务所（以下简称本所）接受浙江亨通控股股份有限公司 （以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、 《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会 《上市公司股东会规则》（以下简称《股东会规则》）等法律法规、规章、规范 性文件以及《浙江亨通控股股份有限公司章程》（以下简称《公司章程》）的规 定，指派律师现场出席了公司于 2025 年 9 月 16 日召开的 2025 年第二次临时股 东大会（以下简称本次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师对本次股东会所涉及的有关事项进行了审查， 查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证，公司已向本所披露一切足以影响本法律意见书出具的事 实并提供了本所为出具本法律意见书所要求公司提供的原始书面材料、副本材料、 复印材料、承诺函或证明，并无隐瞒记载、虚假陈述和重大遗漏之处；公司提供 给本所的文件和材料是真实、准确、完整和有效的，且文件材料为副本或复印件 的，其与原件一致和相符。 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 ...

证券代码：600226 证券简称：亨通股份 公告编号：2025-046 浙江亨通控股股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 本次股东大会由公司董事会召集，公司董事长崔巍先生主持会议。大会采用现场 投票与网络投票相结合的表决方式，会议的召集、召开以及表决方式符合《公司 法》等法律、法规和《公司章程》的有关规定 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 16 日 (二)股东大会召开的地点：浙江省湖州市德清县玉屏路地理信息小镇 C15 幢公司 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 525 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 999,688,352 | | 3、出席会议的股东所持有表决权 ...

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

Company Overview - Zhejiang Hengtong Holdings Co., Ltd. is located in Deqing County, Huzhou City, Zhejiang Province, and was established on May 11, 1999. The company was listed on November 16, 1999 [2] - The main business involves the production and sales of biopesticides, veterinary drugs, feed additives, and related services such as combined heat and power [2] - The revenue composition includes: 67.62% from electrolytic copper foil, 16.17% from electricity and steam, 16.14% from veterinary drugs, and 0.06% from other businesses [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 818 million yuan, representing a year-on-year growth of 45.80%. The net profit attributable to the parent company was 127 million yuan, with a year-on-year increase of 8.91% [2] - Since its A-share listing, the company has distributed a total of 709 million yuan in dividends, with no dividends paid in the last three years [3] Stock Performance - On September 12, the stock price increased by 2.19%, reaching 3.73 yuan per share, with a trading volume of 319 million yuan and a turnover rate of 2.93%. The total market capitalization is 11.094 billion yuan [1] - Year-to-date, the stock price has risen by 46.27%, with a 5-day increase of 5.37%, a 20-day increase of 28.18%, and a 60-day increase of 42.37% [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 29, where it recorded a net purchase of 48.0576 million yuan [1]

Market Overview - The participating fund sector increased by 0.02% compared to the previous trading day, with Hengtong Optic-Electric leading the gains [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Individual Stock Performance - Hengtong Optic-Electric (600226) closed at 3.61, up 3.14%, with a trading volume of 926,600 shares and a turnover of 332 million yuan [1] - Changjiang Securities (000783) closed at 7.93, up 1.41%, with a trading volume of 906,100 shares and a turnover of 713 million yuan [1] - Other notable performers include: - Electric Power Media (000917) at 7.65, up 1.19% [1] - Guomai Technology (002093) at 11.64, up 0.87% [1] - Industrial and Commercial Bank of China (601398) at 7.47, up 0.54% [1] Fund Flow Analysis - The participating fund sector experienced a net outflow of 1.348 billion yuan from institutional investors, while retail investors saw a net inflow of 902 million yuan [2] - Notable net inflows from retail investors include: - Changjiang Securities with a net inflow of 103 million yuan [3] - Industrial and Commercial Bank of China with a net inflow of 95.78 million yuan [3] - Conversely, significant net outflows from institutional investors were observed in: - Junzheng Group (601216) with a net outflow of 440 million yuan [2] - Guolian Minsheng (601456) with a net outflow of 27.5 million yuan [2]

浙江亨通控股股份有限公司 2025 年第二次临时股东大会会议资料 会 议 议 程 时 间： 1、现场会议时间：2025 年 9 月 16 日下午 13:00 开始 2、网络投票时间：2025 年 9 月 16 日，采用上海证券交易所网络投票系统，通过交易 系统投票平台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 地 点：浙江省湖州市德清县玉屏路地理信息小镇 C15 幢公司会议室 浙江亨通控股股份有限公司 2025 年第二次临时股东大会会议资料 二○二五年九月十六日 1 浙江亨通控股股份有限公司 2025 年第二次临时股东大会会议资料 主要议程： 一、主持人宣布大会开始，宣布股东到会情况 二、推举计票和监票人员 三、审议议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于修订《公司章程》的议案 | | 2.00 | 关于修订公司部分治理制度的议案 | | 2.01 | 关于修订《股东会议事规则》的议案 | | 2.02 ...

Core Viewpoint - The company, Hengtong Co., Ltd. (亨通股份), is actively engaged in the production and sales of electrolytic copper foil, veterinary pharmaceuticals, feed additives, and related thermal power supply services, focusing on high-end copper foil products [1] Group 1: Business Overview - The main business areas of the company include electrolytic copper foil, veterinary pharmaceuticals, feed additives, and thermal power supply [1] - The company is advancing in the electrolytic copper foil sector by developing ultra-low profile copper foil products such as HVLPⅢ, RTF-Ⅲ, and carrier copper foil [1] Group 2: Product Development - The company is committed to high-end copper foil product development and has successfully mass-produced high-value-added products like reverse copper foil (RTF), low-profile copper foil (LP), and high-temperature extended copper foil (HTE) [1] - These high-value products have already been applied to downstream customers, indicating successful market integration [1]

亨通股份(600226)今日涨停，全天换手率6.08%，成交额6.35亿元，振幅11.82%。龙虎榜数据显示，沪 股通净卖出1922.56万元，营业部席位合计净买入6728.32万元。 资金流向方面，今日该股主力资金净流入1.08亿元，其中，特大单净流入7908.74万元，大单资金净流入 2861.19万元。近5日主力资金净流入7274.13万元。 8月26日公司发布的半年报数据显示，上半年公司共实现营业收入8.18亿元，同比增长45.80%，实现净 利润1.27亿元，同比增长8.91%。（数据宝） 亨通股份8月29日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 5207.83 | | | 买二 | 沪股通专用 | 3275.08 | | | 买三 | 中信证券股份有限公司上海分公司 | 3072.12 | | | 买四 | 上海证券有限责任公司临平路证券营业部 | 1820.27 | | | 买五 | 高盛(中国)证券有限责 ...

格隆汇8月27日｜华鑫证券研报指出，亨通股份2025年上半年实现归母净利润1.27亿元，同比+8.91%。 分季度来看，2025Q2实现归母净利润0.57亿元，同比+6.49%，环比-18.90%。2025H1公司围绕转型升级 发展战略，聚焦主责主业，加大研发力度，持续开展电解铜箔高端产品、生物合成产品的技术研发与项 目建设，拓展国内外市场，提升公司经营能力和可持续发展能力。公司加强自主研发，铜箔业务转好， 该行预测公司2025-2027年归母净利润分别为2.78、3.47、4.34亿元，当前股价对应PE分别为36.7、 29.4、23.5倍，首次覆盖公司，给予"买入"投资评级。 ...

Investment Rating - The report initiates coverage on the company with a "Buy" investment rating [10] Core Views - The copper foil business is showing signs of improvement, which is a key driver for revenue growth [6] - The company reported a 45.8% year-on-year increase in revenue for the first half of 2025, primarily due to increased sales of copper foil products [5][6] - The net profit attributable to shareholders increased by 8.91% year-on-year, driven by profit growth from the steam business and increased investment income [5][6] Financial Performance - In H1 2025, the company achieved revenue of 818 million yuan, with a significant contribution from the copper foil segment, which saw a 131.33% increase in sales volume [5][6] - The revenue from copper foil products reached 550 million yuan, accounting for 67.59% of total revenue [6] - The company’s financial expenses increased due to higher borrowing costs, while R&D expenses rose significantly due to increased investment in copper foil and biological synthesis product development [7] Business Strategy - The company is focusing on its core business and actively advancing its copper foil projects, with ongoing construction of production capacity for electronic circuit copper foil and lithium battery copper foil [8][9] - The company plans to enhance its R&D capabilities and expand its market presence both domestically and internationally [8] Profit Forecast - The company forecasts net profits attributable to shareholders of 278 million yuan, 347 million yuan, and 434 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 36.7, 29.4, and 23.5 [10][12]